LB Pharmaceuticals Inc granted an equity award to their new Senior Vice President of Regulatory Affairs, James Rawls, under the 2025 Equity Incentive Plan. The award includes an option to purchase 90,000 shares of common stock at an exercise price of $14.61 per share. LB-102, the company’s lead product candidate, is a Phase 3-ready oral, small molecule for schizophrenia and bipolar depression, demonstrating positive results in Phase 2 trials. LB Pharmaceuticals aims to develop innovative therapies for various neuropsychiatric disorders, with LB-102 potentially becoming the first benzamide antipsychotic drug approved in the US.

Read more at GlobeNewswire: LB Pharmaceuticals Reports Inducement Grant to New Employee